Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MediPharm Labs Launches New GMP Products to the Australian Medical Cannabis Market
Details : Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agit...
Brand Name : Pink Kush
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 27, 2023
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabis-derived Therapy
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agit...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 31, 2023
Lead Product(s) : Cannabis-derived Therapy
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Avicanna
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Avicanna and Medipharm intend to commercialize various formulations of Avicanna’s proprietary cannabinoid-based Self-Emulsifying Drug Delivery Systems (SEDDS) technology capsules for the Canadian and international markets.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 26, 2023
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Avicanna
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study
Details : Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agit...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 01, 2023
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabis-derived Therapy
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study
Details : Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agit...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 01, 2023
Lead Product(s) : Cannabis-derived Therapy
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : National Institutes of Health
Deal Size : $16.0 million
Deal Type : Funding
MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC
Details : MediPharmto design, manufacture and supply a liquid oral cannabis study drug for the Phase 2 Life’s end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) study, to be conducted in the U.S., across 20 sites, to treat hospice-eligible patients dia...
Brand Name : T2:C100
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 09, 2022
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : National Institutes of Health
Deal Size : $16.0 million
Deal Type : Funding
Lead Product(s) : Cannabigerol,Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products
Details : New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia strains.
Brand Name : CBG:CBD
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 05, 2022
Lead Product(s) : Cannabigerol,Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol,Cannabigerol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products
Details : Naturally derived oil and inhalable cannabigerol (cannabinoid) products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 05, 2022
Lead Product(s) : Cannabidiol,Cannabigerol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : McMaster University
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : McMaster University researchers using MediPharm Labs’ CBD50 formula and CBD:THC 10:2 formulation, which has the same as MediPharm Labs’ CBD25, have received a No Objection Letter from Health Canada to begin recruiting human subjects for a placebo-con...
Brand Name : CBD50
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 31, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : McMaster University
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : McMaster University
Deal Size : Undisclosed
Deal Type : Agreement
Details : Three initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD (cannabidiol) drug candidates for multiple indications including Pain, Insomnia associated with Major Depression, and Uremic Pruritus.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 21, 2021
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : McMaster University
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?